A Tylenol recall has been declared for merchandise produced at a McNeil Consumer Healthcare facility by its parent business, Johnson and Johnson. The 5th Tylenol recall within the past year was announced with a congressional investigation in progress of McNeil Consumer Healthcare’s quality manage procedures. A musty scent coming from the containers triggered the latest recall of the popular over-the-counter medicine.
Tylenol 8-Hour recall
The Tylenol recall was talked about Monday. That had been the latest news on it. 128,000 bottles of 50-count Tylenol 8-Hour Caplets were taken back voluntarily by Johnson and Johnson’s McNeil Consumer Healthcare division. The Tylenol 8-hour products had a “musty or moldy odor” that had been complained about in the U.S. and Puerto Rico which called for McNeil to initiate the recall, reports the NY Times. Before March, when the Fort Washington, Pennsylvania, plant had been closed, it made the batch of Tylenol that the company is now recalling. The moldy smell probably originated from the exact same thing that caused the recall in January, June and July with merchandise that originated from the McNeil factory in Puerto Rico and that had been a chemical that got to the Tylenol when the business had been treating wooden transport pallets.
Tylenol recalls a continuous series
Because Johnson and Johnson have had a number of recalls this year, Congress has decided to look into it. Due to nausea, stomach pain, vomiting and diarrhea, five lots of 100-count Tylenol Arthritis Pain were recalled, accounts Cable News Network, just last Nov. Then in December, there was yet another recall. This recalled of the lots. The recall had been then expanded even further to non-prescription drugs causing scent and nausea with things such as Tylenol and Motrin. In May, 50 children’s medicines were recalled because of quality control and safety concerns.
Not controlling things well
The McNeil plant was closed by Johnson and Johnson. This had been done in April. The U.S. Food and drug administration looked at the plant and found that there were many violations which has brought on Johnson and Johnson to revamp all of the plant’s quality control plans, accounts Reuters. The FDA found thick dust, grime and contaminated drug ingredients. Drugs manufactured at the Fort Washington plant contributed sales of about $650 million a year to Johnson and Johnson’s bottom line. Bloomberg accounts that the recalls and plant closings will reduce the company’s sales this year by about $600 billion.
New York Times
prescriptions.blogs.nytimes.com/2010/10/18/more-trouble-with-tylenol/?partner=rss and emc=rss